Cause-specific mortality following sustained virologic response in hepatitis C patients treated with direct-acting antivirals: a standardized mortality ratio analysis.

ABSTRACT: Direct-acting antivirals (DAAs) achieve high sustained virologic response (SVR) rates in patients with hepatitis C virus (HCV) infection. However, the long-term prognosis and cause-specific mortality post-SVR remain unclear. This study analyzed 1753 HCV-infected patients without a history of hepatocellular carcinoma treatment who achieved SVR with DAAs and did not develop cancer. Liver disease-related (LDR) and non-LDR mortalities were assessed using age- and sex-adjusted standardized mortality ratios (SMRs) compared with the general population. During a mean follow-up of 59.2 months, 122 patients died. The SMR for all-cause mortality was 1.050 (p = 0.588). The SMRs for LDR and non-LDR mortalities were 7.819 (p < 0.001) and 0.566 (p < 0.001), respectively. The SMR for extrahepatic malignan

SUBMITTER: Mawatari S 

PROVIDER: S-EPMC12749750 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature